SynthesisWorld journal of surgical oncology2025
Safety and efficacy of salvage surgery for unresectable hepatocellular carcinoma after conversion with triple therapy: a systematic review and meta-analysis of data from Chinese patients.
Synthesis in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundConversion therapy based on vascular intervention combined with targeted immunotherapy has gradually improved treatment outcomes for hepatocellular carcinoma (HCC). Salvage surgery after conversion therapy is worthy of attention. The aim of this study is to summarize the safety and efficacy of salvage surgery after triple therapy for patients with HCC.
methodsThe PubMed, EMBASE, Cochrane Library, Web of Science, and Chinese databases were used to screen eligible studies evaluating the clinical efficacy and safety of triple therapy for patients with unresectable hepatocellular carcinoma (uHCC) up to April 2025. Survival outcomes, pathological characteristics, and perioperative features were extracted for further analysis.
resultsThis meta-analysis included 15 studies of 742 uHCC patients who underwent surgery after triple therapy. The median overall survival (mOS) could not be performed in the present meta-analysis, as most trials did not reach mOS. The pooled one-year overall survival (OS) rate and two-year OS rate was 0.92 (95% confidence interval (CI) = 0.89–0.96) and 0.84 (95% CI = 0.75–0.92), respectively. In terms of pathological characteristics, the pooled incidence of microvascular invasion (MVI) was 0.20 (95% CI = 0.10–0.30), and the pooled pathologic complete response (pCR) rate was 0.40 (95% CI = 0.29–0.52). The pooled postoperative complication rate of posthepatectomy liver failure (PHLF) and Clavien–Dindo (CD) III–V were 0.23 (95% CI = 0.15–0.30) and 0.11 (95% CI = 0.06, 0.16), respectively.
conclusionSalvage surgery after conversion with triple therapy might have promising clinical benefits, efficacy and safety for patients with unresectable hepatocellular carcinoma. Further prospective studies are needed to validate these findings and improve HCC management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.